| Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase HE Bryant, N Schultz, HD Thomas, KM Parker, D Flower, E Lopez, S Kyle, ... Nature 434 (7035), 913-917, 2005 | 5827 | 2005 |
| Anticancer chemosensitization and radiosensitization by the novel poly (ADP-ribose) polymerase-1 inhibitor AG14361 CR Calabrese, R Almassy, S Barton, MA Batey, AH Calvert, ... Journal of the National Cancer Institute 96 (1), 56-67, 2004 | 592 | 2004 |
| Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441 Y Zhao, HD Thomas, MA Batey, IG Cowell, CJ Richardson, RJ Griffin, ... Cancer research 66 (10), 5354-5362, 2006 | 545 | 2006 |
| Preclinical selection of a novel poly (ADP-ribose) polymerase inhibitor for clinical trial HD Thomas, CR Calabrese, MA Batey, S Canan, Z Hostomsky, S Kyle, ... Molecular cancer therapeutics 6 (3), 945-956, 2007 | 354 | 2007 |
| Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition N Johnson, YC Li, ZE Walton, KA Cheng, D Li, SJ Rodig, LA Moreau, ... Nature medicine 17 (7), 875-882, 2011 | 314 | 2011 |
| Therapeutic Potential of Poly(ADP-ribose) Polymerase Inhibitor AG014699 in Human Cancers With Mutated or Methylated BRCA1 or BRCA2 Y Drew, EA Mulligan, WT Vong, HD Thomas, S Kahn, S Kyle, ... Journal of the national cancer institute 103 (4), 334-346, 2011 | 304 | 2011 |
| Novel tricyclic poly (ADP-ribose) polymerase-1 inhibitors with potent anticancer chemopotentiating activity: design, synthesis, and X-ray cocrystal structure SS Canan Koch, LH Thoresen, JG Tikhe, KA Maegley, RJ Almassy, J Li, ... Journal of medicinal chemistry 45 (23), 4961-4974, 2002 | 166 | 2002 |
| Identification of potent nontoxic poly (ADP-Ribose) polymerase-1 inhibitors: chemopotentiation and pharmacological studies CR Calabrese, MA Batey, HD Thomas, BW Durkacz, LZ Wang, S Kyle, ... Clinical cancer research 9 (7), 2711-2718, 2003 | 142 | 2003 |
| Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma RA Noble, N Bell, H Blair, A Sikka, H Thomas, N Phillips, S Nakjang, ... Haematologica 102 (7), 1247, 2017 | 134 | 2017 |
| 6-thioguanine selectively kills BRCA2-defective tumors and overcomes PARP inhibitor resistance N Issaeva, HD Thomas, T Djurenovic, JE Jaspers, I Stoimenov, S Kyle, ... Cancer research 70 (15), 6268-6276, 2010 | 127 | 2010 |
| Inhibition of poly (ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma RA Daniel, AL Rozanska, HD Thomas, EA Mulligan, Y Drew, ... Clinical Cancer Research 15 (4), 1241-1249, 2009 | 102 | 2009 |
| DNA-PK—a candidate driver of hepatocarcinogenesis and tissue biomarker that predicts response to treatment and survival L Cornell, JM Munck, C Alsinet, A Villanueva, L Ogle, CE Willoughby, ... Clinical Cancer Research 21 (4), 925-933, 2015 | 97 | 2015 |
| Poly (ADP-ribose) polymerase-1 (PARP-1) pharmacogenetics, activity and expression analysis in cancer patients and healthy volunteers T Zaremba, HD Thomas, M Cole, SA Coulthard, ER Plummer, NJ Curtin Biochemical Journal 436 (3), 671-679, 2011 | 84 | 2011 |
| A clinical and pharmacokinetic study of the combination of carboplatin and paclitaxel for epithelial ovarian cancer N Siddiqui, AV Boddy, HD Thomas, NP Bailey, L Robson, MJ Lind, ... British journal of cancer 75 (2), 287-294, 1997 | 81 | 1997 |
| Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly (ADP-ribose) polymerase inhibitor AG-014699 RA Daniel, AL Rozanska, EA Mulligan, Y Drew, HD Thomas, ... British journal of cancer 103 (10), 1588-1596, 2010 | 71 | 2010 |
| Carboplatin in combination with paclitaxel in advanced ovarian cancer: dose determination and pharmacokinetic and pharmacodynamic interactions. AH Calvert, A Boddy, NP Bailey, N Siddiqui, A Humphreys, A Hughes, ... Seminars in oncology 22 (5 Suppl 12), 91-8; discussion 99, 1995 | 70 | 1995 |
| Vasoactivity of AG014699, a clinically active small molecule inhibitor of poly (ADP-ribose) polymerase: a contributory factor to chemopotentiation in vivo? M Ali, BA Telfer, C McCrudden, M O'Rourke, HD Thomas, M Kamjoo, ... Clinical cancer research 15 (19), 6106-6112, 2009 | 68 | 2009 |
| Design, synthesis, and evaluation of 3, 4-dihydro-2 H-[1, 4] diazepino [6, 7, 1-hi] indol-1-ones as inhibitors of poly (ADP-ribose) polymerase JG Tikhe, SE Webber, Z Hostomsky, KA Maegley, A Ekkers, J Li, XH Yu, ... Journal of medicinal chemistry 47 (22), 5467-5481, 2004 | 67 | 2004 |
| Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy CE Willoughby, Y Jiang, HD Thomas, E Willmore, S Kyle, A Wittner, ... The Journal of clinical investigation 130 (1), 258-271, 2020 | 66 | 2020 |
| Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules J Murray, H Thomas, P Berry, S Kyle, M Patterson, C Jones, G Los, ... British journal of cancer 110 (8), 1977-1984, 2014 | 65 | 2014 |
